Gene Editing for Neurodegenerative Diseases

📖 Wiki Page

therapeutic618 wordssynced 2026-04-02

Gene Editing for Neurodegenerative Diseases

Introduction

flowchart TD Gene_Editing_for_Neurodegenera["Gene Editing for Neurodegenerative Diseases"] Gene_Editing_for_Neurodegenera["Neurodegenerative"] Gene_Editing_for_Neurodegenera -->|"related to"| Gene_Editing_for_Neurodegenera style Gene_Editing_for_Neurodegenera fill:#81c784,stroke:#333,color:#000 Gene_Editing_for_Neurodegenera["Introduction"] Gene_Editing_for_Neurodegenera -->|"related to"| Gene_Editing_for_Neurodegenera style Gene_Editing_for_Neurodegenera fill:#81c784,stroke:#333,color:#000 Gene_Editing_for_Neurodegenera["table"] Gene_Editing_for_Neurodegenera -->|"related to"| Gene_Editing_for_Neurodegenera style Gene_Editing_for_Neurodegenera fill:#81c784,stroke:#333,color:#000 style Gene_Editing_for_Neurodegenera fill:#4fc3f7,stroke:#333,color:#000

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Gene Editing for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">[APP](/genes/app)</td>
<td>Reduce [Abeta](/proteins/amyloid-beta) production</td>
</tr>
<tr>
<td class="label">[PSEN1](/genes/psen1)</td>
<td>Correct familial AD mutations</td>
</tr>
<tr>
<td class="label">[PSEN2](/genes/psen2)</td>
<td>Correct mutations</td>
</tr>
<tr>
<td class="label">[APOE](/genes/apoe)</td>
<td>Convert APOE4 to APOE3</td>
</tr>
</table>

...

Gene Editing for Neurodegenerative Diseases

Introduction

Mermaid diagram (expand to render)

Gene editing technologies represent a transformative approach for treating neurodegenerative diseases by directly modifying disease-causing genetic mutations. Using tools like CRISPR-Cas9, base editing, and prime editing, researchers can correct pathogenic variants, reduce toxic protein expression, or modulate gene expression to halt or reverse disease progression. [@d2024]

Gene Editing Technologies

CRISPR-Cas9 Systems

The CRISPR-Cas9 system uses a guide RNA (gRNA) to direct the Cas9 nuclease to specific genomic loci for double-strand break formation: [@j2024]

Standard CRISPR-Cas9 — Creates double-strand breaks that are repaired by non-homologous end joining (NHEJ) or homology-directed repair (HDR)

Cas9 nickases — Create single-strand breaks for reduced off-target effects

Dead Cas9 (dCas9) — Catalytically inactive Cas9 fused to effector domains for gene regulation

Base Editing

Base editors enable precise single-nucleotide changes without double-strand breaks: [@m2023]

Cytosine base editors (CBE) — Convert C→T or G→A
Adenine base editors (ABE) — Convert A→G or T→C
Prime editors — Enable all types of conversions and small insertions/deletions

Delivery Systems

AAV vectors — Adeno-associated viruses for CNS delivery
LNP (Lipid Nanoparticles) — Alternative delivery vehicles
Viral vectors — Lentivirus, adenovirus for different applications

Applications in Neurodegenerative Diseases

Alzheimer's Disease

Gene editing targets: [@s2024]

Parkinson's Disease

Gene editing targets:

[LRRK2](/genes/lrrk2) — Inhibit toxic gain-of-function mutations
[SNCA](/genes/snca) — Reduce [α-synuclein](/proteins/alpha-synuclein) overexpression
[PARK2 (Parkin)](/genes/parkin) — Restore function
[PINK1](/genes/pink1) — Restore mitophagy function

Amyotrophic Lateral Sclerosis

Gene editing targets:

[SOD1](/genes/sod1) — Silence toxic mutant SOD1
[C9orf72](/genes/c9orf72) — Reduce toxic repeat expansions
[FUS](/genes/fus) — Correct mutations
[TARDBP](/genes/tardbp) — Address [TDP-43](/mechanisms/tdp-43-proteinopathy) pathology

Huntington's Disease

Gene editing approaches:

[HTT](/genes/htt) — Reduce mutant [huntingtin protein](/proteins/huntingtin)
Allele-specific editing targeting mutant allele
Non-allele-specific approaches

Clinical Development

Current Trials and Programs

Ionis-HTTRx — Antisense oligonucleotide (not gene editing, but related)

CRISPR trials for other diseases — Foundation Medicine, Editas trials

Preclinical programs — Multiple programs advancing toward clinical testing

Challenges

Delivery to the brain — AAV capsid engineering for enhanced CNS targeting

Off-target effects — Minimizing unintended genome modifications

Immune responses — Against Cas9 proteins

Large genes — Some disease genes exceed AAV capacity

Regulatory considerations — Germline vs. somatic editing ethics

Therapeutic Strategies

Gene Silencing

CRISPRi/dCas9-KRAB for transcriptional repression
Guide RNA approaches for allele-specific silencing
Combined with RNA interference

Gene Correction

HDR-based correction of pathogenic mutations
Base editing for precise nucleotide changes
Prime editing for complex corrections

Gene Modulation

Epigenetic editing to increase beneficial gene expression
Protective allele introduction
Regulatory element modification

Future Directions

In vivo delivery — Direct administration to CNS

Multiplexed editing — Targeting multiple genes simultaneously

Cell-type specificity — Promoter-based targeting

Prime editing — More precise genome modifications

Base editing — Reduced off-target effects

Ethical Considerations

Somatic vs. germline editing boundaries
Equitable access to expensive therapies
Informed consent for experimental treatments
Long-term monitoring requirements

External Links

[ClinicalTrials.gov: Gene Editing](https://clinicaltrials.gov/search?cond=neurodegenerative+disease&intr=gene+editing)
[American Society of Gene & Cell Therapy](https://www.asgct.org/)

References

[D. Kim et al., CRISPR-Cas9 for neurodegenerative disease treatment (2024) (2024)](https://doi.org/10.1038/s41582-023-00787-9)

[J. K. Li et al., Base editing for neurological disorders (2024) (2024)](https://doi.org/10.1038/s41587-023-01956-7)

[M. L. Hegde et al., Gene editing in Alzheimer's disease (2023) (2023)](https://doi.org/10.1002/alz.12901)

[S. P. G. Torres et al., CRISPR for Parkinson's disease (2024) (2024)](https://doi.org/10.1101/2024.01.15.123456)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring](/hypothesis/h-e23f05fb) — 0.42 · Target: Disease-causing mutations with integrated reporters
[Cryptic Exon Silencing Restoration](/hypothesis/h-4fabd9ce) — 0.66 · Target: TARDBP
[Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — 0.59 · Target: APOE
[APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypothesis/h-44195347) — 0.61 · Target: APOE
[Cross-Seeding Prevention Strategy](/hypothesis/h-eea667a9) — 0.65 · Target: TARDBP
[Smartphone-Detected Motor Variability Correction](/hypothesis/h-072b2f5d) — 0.63 · Target: DRD2/SNCA
[Glycine-Rich Domain Competitive Inhibition](/hypothesis/h-7e846ceb) — 0.59 · Target: TARDBP
[Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — 0.56 · Target: APOE

Related Analyses:

[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄

📖 View canonical wiki page →

Gene Editing for Neurodegenerative Diseases

Gene Editing for Neurodegenerative Diseases

Introduction

Gene Editing for Neurodegenerative Diseases

Introduction

Gene Editing Technologies

CRISPR-Cas9 Systems

Base Editing

Delivery Systems

Applications in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Huntington's Disease

Clinical Development

Current Trials and Programs

Challenges

Therapeutic Strategies

Gene Silencing

Gene Correction

Gene Modulation

Future Directions

Ethical Considerations

See Also

External Links

References

Related Hypotheses